ADDED
There were 63,808,716 shares of registrant s Common Stock, par value $0.00001 per share, outstanding as of February 18, 2026.
If we are unable to discover and develop new product candidates, our business would be adversely affected.
Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity.
Unstable market and macroeconomic conditions, including tariffs or trade policy, may have serious adverse consequences on our business, financial condition and stock price.
If we require additional capital, there may be dilution to our existing stockholders.
We rely on J J Innovative Medicines ( JNJ ) to develop Icotyde in additional indications and successfully commercialize Icotyde.
Potential business combinations or other strategic transactions may disrupt our business or divert management s attention.
If our partners do not satisfy their obligations under our agreements with them, or if they terminate our partnerships with them, we may not be able to develop or successfully commercialize our partnered product candidates successfully.
If the FDA or comparable foreign regulatory authorities approve generic versions of our approved product candidates, if any, or such authorities do not grant our approved product candidates appropriate periods of data or market exclusivity before approving a generic version, sales of our approved drug candidates could be adversely affected.
(referred to as Protagonist, the Company, we, our or us ) is an integrated discovery and development company with a validated technology platform.
REMOVED
There were 61,384,289 shares of registrant s Common Stock, par value $0.00001 per share, outstanding as of February 19, 2025.
Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity, including being required by an independent data monitoring committee or regulatory authorities to delay or halt or clinical trials, or if such side effects or adverse events are sufficiently severe or prevalent, to suspend or cease altogether further development of our product candidates.
We have never generated any revenue from product sales and may never be profitable.
Unstable market and macroeconomic conditions including elevated and sustained inflation and changes in trade policies, including tariffs or other trade restrictions or the threat of such actions, may have serious adverse consequences on our business, financial condition and stock price.
Raising additional capital may cause dilution to our existing stockholders.
We rely on J J Innovative Medicines ( JNJ ) to continue the development of product candidates subject to our license and collaboration with JNJ, and to successfully commercialize any resulting products, and we rely on Takeda Pharmaceuticals USA, Inc.
( Takeda ) to successfully commercialize any products resulting from our collaboration agreement with Takeda.
We may face risks to our business arising from outbreaks of disease, epidemics and pandemics, including risks to our ongoing and planned clinical trials and pre-clinical and discovery research.
Unstable market and economic conditions, including elevated and sustained inflation, may have serious adverse consequences on our business, financial condition and stock price.
Business OVERVIEW We are a discovery through late-stage development biopharmaceutical company focused on peptide therapeutics.